All India Institute of Medical Science (AIIMS) Director Randeep Guleria said that two covid-19 vaccine candidates that are in the phase 3 trials could be eligible for emergency use in India by january 2021.
Oxford-AstraZeneca Covid-19 vaccine candidate is currently in the final phase in India.If everything goes well,India might get the first slot by January 2021 and the Pune based firm could apply for Oxford Vaccine for emergency use so they dubbed it as Covishield in India.
Recently United Kingdom(UK) gave its approval to the coronavirus vaccine Pfizer for emergency use.So now India is in the race,experts said,India’s own vaccine might be available immediately right after the phase 3 trials are over and drug regulators convinced of its efficiency against covid-19.
Ram Vishwakarma of the council and scientific and Industrial Research-Indian Institute of Integrative Medicine (CSIR-IIIIM) declared that the emergency use authorisation (EUA) procedure in India is similar to the UK,the European Union and the US.
Finally AIIMS director Randeep Guleria ,who is also a member of national task force on covid-19 management told that there are two vaccine in phase 3 trials,Serum Institute’s Covishield and Bharat Biotech’s Covaxin could be available for emergency use in India by the first month of 2021.If it happens then first it will be provided to vulnerable and frontline workers who are in this battle since the beginning of 2020.
What PM Modi says on Coronavirus Vaccine
Coronavirus Vaccine could be ready for India in few weeks and Vaccination would begin once the centre gets an approval from the scientists and pricing of the vaccine and its distribution will be discussed with the states.
Disclaimer:All information is officially announced by the Indian government.